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ABSTRACT: Tissue engineering is now contributing to new developments in several clinical fields,
and mesenchymal stem cells derived from adipose tissue (hASCs) may provide a novel opportunity
to replace, repair and promote the regeneration of diseased or damaged musculoskeletal tissue. Our
interest was to characterize and differentiate hASCs isolated from twenty-three donors. Proliferation,
CFU-F, cytofluorimetric and histochemistry analyses were performed. HASCs differentiate into os-
teogenic, chondrogenic, and adipogenic lineages, as assessed by tissue-specific markers such as
alkaline phosphatase, osteopontin expression and deposition of calcium matrix, lipid-vacuoles for-
mation and Glycosaminoglycans production. We also compared osteo-differentiated hASCs cultured
on monolayer and loaded on biomaterials routinely used in the clinic, such as hydroxyapatite, can-
cellous human bone fragments, deproteinized bovine bone granules, and titanium. Scaffolds loaded
with pre-differentiated hASCs do not affect cell proliferation and no cellular toxicity was observed.
HASCs tightly adhere to scaffolds and differentiated-hASCs on human bone fragments and bovine
bone granules produced, respectively, 3.4- and 2.1-fold more calcified matrix than osteo-differentiat-
ed hASCs on monolayer. Moreover, both human and deproteinized bovine bone is able to induce os-
teogenic differentiation of CTRL-hASCs. Although our in vitro results need to be confirmed in in vivo
bone regeneration models, our data suggest that hASCs may be considered suitable biological tools
for the screening of innovative scaffolds that would be useful in tissue engineering. (Int J Artif Organs
2008; 31: ) 
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INTRODUCTION
A promising way to promote tissue regeneration inclu-
des the use of constructs to be inserted in the defect site,
using techniques developed by tissue engineering. These
constructs may be generated with autologous cells,
either terminally differentiated or undifferentiated, and
loaded on suitable natural or synthetic scaffolds.
Recently, the interest in Mesenchymal Stem Cells
(MSCs) for musculoskeletal tissue regeneration has signi-
ficantly increased due to their wide characterization, their
confirmed multipotential ability, and their availability (1, 2).
Indeed, many in vitro and in vivo studies have shown the
use of MSCs in the regeneration of bone and cartilage
defects (3-7). Although bone marrow represents the most
common source of MSC (Bone Marrow derived Stromal
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Cells - BMSC), several studies have indicated their pre-
sence in other tissues such as periostium, skeletal mu-
scle, trabecular bone, synovial membrane and adipose
tissue (8-10). It has been previously shown that human
Adipose-derived Stem Cells (hASCs) are able to diffe-
rentiate in vitro into bone, cartilage, fat, muscle, en-
dothelial and neuronal-like cells (11-16), and since they
can be easily isolated from lipoaspirated tissue (14),
their use in research and for clinical applications may
have several advantages. Furthermore, adipose tissue
derived from the minimally invasive procedure of lipo-
suction is usually discarded, and it has been shown
that a significant number of hASCs can be isolated
from a few milliliters of raw tissue. Moreover, they do
not lose their proliferation rate and differentiation po-
tential after cryopreservation (17). In addition, as seve-
ral authors have reported regarding stromal cells deri-
ved from BMSC, these types of cells, isolated from the
Stromal Vascular Fraction, are not negatively affected
by the age of the donor (18,19). 
In this study, we describe the mesenchymal immu-
nophenotype of hASCs and their in vitro osteogenic
and chondrogenic ability. In particular, we analyze the
influence of a three-dimensional environment used for
culturing hASCs, both differentiated and undifferentia-
ted, on natural or synthetic scaffolds, which are used in
orthopedic and dental applications. 
MATERIALS AND METHODS
Materials and antibodies
All materials and tissue culture reagents were pur-
chased from Sigma-Aldrich (Milan, Italy),  unless
otherwise stated, and type I collagenase was purcha-
sed from Worthington (Lakewood, NJ, USA). Antibodies
used in flow cytometry and immunofluorescence expe-
riments are shown in Table I. 
Isolation and culture expansion of Human
Adipose tissue-derived Stem Cells (hASCs)
Subcutaneous fat aspirates were obtained from 23
donors (mean age 38 years, range 21-60 years, BMI
22-40, 85% female), after written consent and Institu-
tional Review Board (IRB) approval. Primary cultures of
the stromal vascular fraction (SVF) were established as
previously described (11). Briefly, the matrix was dige-
sted with 0.075% type I collagenase in a shaking water
bath at 37°C for 30 minutes and then centrifuged for 10
minutes at 1200 g to separate the SVF from adipocy-
tes, cellular debris and undigested tissue. Cells derived
from the SVF were plated in control medium (media
composition is listed in Table II), at 105 cells/cm2. The
cells were maintained at 37°C in a humidified atmo-
TABLE I - ANTIBODIES RAISED AGAINST HUMAN EPITOPES USED IN EXPERIMENTS OF FLOW CYTOMETRY AND
IMMUNOFLUORESCENCE
Primary Antibody Clone Conjug. Supplier
mAb anti-CD 13 22A5 FITC Ancell (Bayport, MN, USA)
mAb anti-CD 14 UCHM1 FITC “
mAb anti-CD 45 C11 FITC “
mAb anti-CD 29 4B7R biotin “
mAb anti-CD 34 43A1 biotin “
mAb anti-CD 49d BU49 biotin “
mAb anti-CD 54 15.2 biotin “
mAb anti-CD 71 DF1513 biotin “
mAb anti-CD 105 N1-3A1 biotin “
mAb anti-CD 44 SFF-2 FITC Alexis Biochemicals (San Diego, CA, USA)
mAb anti-CD 90 90C03 purified Lab Vision (Fremont, CA, USA)
mAb anti-α-tubulin DM1A purified Sigma-Aldrich (Milan, Italy)  
rbAb anti-actin A2066 purified  “  
rbAb anti-osteopontin RB-9097 purified Lab Vision (Fremont, CA, USA)  
mAb anti-collagen II 2B1.5 purified  “       
Secondary detector Conjug. Supplier  
streptavidin R-PE Ancell (Bayport, MN, USA)
sheep anti-mouse IgG antibody FITC Boeringher (Mannheim, Germany)
goat anti-rabbit IgG antibody TRITC Jackson Immunores. (West Grove, PA, USA)
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sphere with 5% CO2. After 24 to 48 hours, nonadherent
cells were discarded and the medium was changed twi-
ce a week. Once they reached 80% of confluence, cells
were detached by means of trypsin/EDTA (0.5% try-
psin/0.2% EDTA) and plated at a density of 104 cells/
cm2 for further expansion.
Flow cytometry and immunofluorescence
analysis
HASCs (3X105 per sample) were washed in PBS/10%
FBS/0.01% NaN3 and incubated with mAbs raised
against CD13, CD14, CD29, CD34, CD44, CD45,
CD49d, CD54, CD71, CD90 and CD105 (see Tab. I) for
30 minutes on ice. Primary antibodies were revealed
either with Streptavidin-PE or FITC conjugated sheep
anti-mouse Ab for 20 minutes at 4°C. Samples were
analyzed using FACS (FACSCalibur flowcytometer - BD
Biosciences Europe, Erembodegem, Belgium) and data
was analyzed using CellQuest software (BD Bioscien-
ces Europe).
Fibroblast – Colony Forming Unit (CFU-F)
assay
The CFU-F assay was performed as previously de-
scribed (20), with minor modifications. HASCs were
plated by limiting dilution in 6-well plates (from 48
cell/cm2 to 1 cell/cm2) and cultured in DMEM/20% FBS.
At day 6, the medium was changed, and at day 10, cel-
ls were fixed with methanol and stained with 0.5% Cry-
stal Violet. The frequency of the CFU-F was established
by scoring individual colonies with respect to the num-
ber of seeded cells. 
Cell lineage differentiation and evaluation of
differentiation markers
Osteogenic differentiation 
At passage 4, hASCs were plated at 104 hASC/cm2 in
control and osteogenic induction medium (Tab. II), repla-
cing the medium twice a week. At day 7, 14, and 21 of
the culture, cells were lysed (Triton X-100 0.1% in ddH2O)
and intracellular alkaline phosphatase activity (ALP) was
measured. Cell lysates were incubated at 37°C in the pre-
sence of 1 mM p-nitrophenylphosphate (pNPP) in alkaline
buffer (100 mM diethanolamine and 0.5 mM MgCl2, pH
10.5) (21). The reaction was stopped with NaOH 1 N and
samples read at 410 nm with the Wallac Victor II plate
reader (Perkin Elmer Western Europe, Monza, Italy). Total
protein content was determined by BCA Protein Assay
(Pierce Biotechnology, Rockford, IL, USA).
To evaluate calcium deposition, 104 hASC/cm2 were
cultured in control and osteogenic media without any cell
detachment for 14 to 21 days. Wells were rinsed with
PBS and fixed with ice-cold 70% ethanol for 1 hour.
Samples were then stained with 40 mM Alizarin Red-S
(ARS) (pH 4.1) for 15 minutes and rinsed with distilled
H2O. Each sample was then incubated with 10% w/v
cetylpyridinium chloride (CPC) in 0.1M phosphate buffer
(pH 7.0) for 30 minutes to extract the stained matrix and
read at 550 nm (22) with the Wallac Victor II plate reader. 
Osteopontin expression was assessed by immunofluo-
rescence experiments: cells cultured on coverslips for 14
days were fixed in 3% paraformaldheyde, permeabilized
for 4 minutes in PBS/0.1% Triton X-100 and then incuba-
ted with a rabbit anti-human osteopontin Ab and a mou-
se anti-human α-tubulin mAb for 60 minutes at RT. The
TABLE II - LINEAGE SPECIFIC DIFFERENTIATION MEDIA
Medium Media Serum Supplementation
Control (CTRL) DMEM 10% FBS none
Adipogenic
- induction DMEM 10% FBS 1µM dexamethasone, 10 µg/mL insulin, 
500 µM IBMX (3-isobutyl-1-methyl-xanthine), 200 µM indomethacin
- maintenance DMEM 10% FBS 10 µg/mL insulin
Osteogenic DMEM 10% FBS 10 nM dexamethasone, 10 mM glicerol-2-phosphate, 
150 µM L-ascorbic acid-2-phosphate, 10nM cholecalciferol
Chondrogenic DMEM 1% FBS 100 nM dexamethasone, 110 mg/L sodium pyruvate, 
150 µM L-ascorbic acid-2-phosphate, 1X ITS, 10 ng/mL TGF-β11
1 Invitrogen-BioSource (Camarillo, CA, USA)
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primary antibodies were revealed with a TRITC conjuga-
ted goat anti-rabbit IgG and a FITC conjugated sheep an-
ti-mouse IgG for 30 minutes at RT.
Chondrogenic differentiation 
Chondrogenic differentiation was obtained either in
monolayer or in pellet culture conditions: 5X105 hASCs
were centrifuged (500 g, 3 min) in a 15 mL centrifuge tu-
be, the pellets were resuspended in control or chondro-
genic induction media (see Tab. II) and then re-centrifu-
ged (500 g, 3 min); media were changed twice a week.
After 21 to 28 days, pellets were fixed in 10% neutral buf-
fered formalin, dehydrated with a series of graded etha-
nol, embedded in paraffin and cut into 10 µm thick sec-
tions. Micromass sections were stained with hematoxy-
lin/eosin or Alcian Blue 8GX; briefly, sections were stai-
ned with Alcian Blue solution (1% w/v in 3% glacial ace-
tic acid, pH2.5) and counterstained with nuclear fast red
(0.1% w/v).
Cells grown on monolayer were also stained with Al-
cian Blue as described above. Alcian Blue dye deposition
was quantified by acquiring digital images with speciali-
zed image analysis software. Deposition was expressed
as the brightness value of several randomly chosen areas
(n=9) of the cellular soma. For sulfated glycosammingly-
cans (GAGs), quantification micromasses of 21 days in
culture were digested by proteinase K (50 µg/mL in 100
mM K2HPO4, pH 8.0) at 56°C, according to a modified
version of the dimethylmethylene blue (DMMB) assay
(23). GAGs content were expressed as µg/pellet using
bovine trachea chondroitin-4-sulfate (0 to 8 µg/mL) as
standard. Immunofluorescence experiments were perfor-
med to evaluate collagen II expression: 21 days differen-
tiated cells grown in monolayer were allowed to adhere
on coverslips for three days, then processed as descri-
bed above, by incubating with a mouse anti-human colla-
gen II mAb and a rabbit anti-human actin Ab for 60 minu-
tes at RT. The primary antibodies were revealed with a
TRITC conjugated goat anti-rabbit IgG and a FITC conju-
gated sheep anti-mouse IgG.
Adipogenic differentiation 
At passage 4, hASCs were plated at 104 hASC/cm2 and
induced to differentiate in adipogenic conditions with a
21-day, scheduled, pulsed induction composed of 48
hours of induction followed by 48 hours of maintenance
(see Tab. II). Adipogenic differentiation was confirmed by
Oil Red O (2% w/v Oil Red O in 60% isopropanol) lipid
droplet staining.
HASC-scaffold constructs
Undifferentiated or osteogenic pre-differentiated hASCs
(105 cells/scaffold) were seeded on porous (60%) hydroxya-
patite blocks (HAP) (kindly provided by Permedica S.p.A.,
Merate, Italy and Biomaterials Research Center, University
of Milan, Italy), human cancellous bone fragments (kindly
provided by the Musculoskeletal Tissue Bank, Lombardy
Region, Italy) titanium screws (Permedica S.p.A., Merate,
Italy) and deproteinized bovine bone granules (Bio-Oss®,
0.25-1 mm, Geistlich Pharma AG, Biomaterials Division,
Wolhusen, Switzerland). Cells were allowed to adhere over-
night to scaffolds in microcentrifuge tubes and then the
scaffolds were transferred to a 24-well plate and cultured
under static conditions either in control or osteogenic me-
dia (Tab. II). To evaluate calcium depots, Alizarin Red S
quantification was performed as described above.
Scanning Electron Microscopy (SEM)
HASCs grown on scaffolds for 14 days were analyzed
by SEM. The constructs were fixed in glutaraldehyde (2%
in 0.1 M sodium cacodylate buffer) overnight at 4°C, and
dehydrated with a series of graded ethanol and exa-
methildisilazane. Samples were mounted on aluminium
stubs, sputter-coated with gold/palladium and were exa-
mined with a scanning electron microscope (JSM-840A,
Jeol Ltd., Tokyo, Japan).
Statistical analysis
Statistical analyses (Student’s t-test and Two-way
ANOVA) were performed using GraphPad Prism v5.00
(GraphPad Software, San Diego, CA, USA). 
RESULTS 
Culture and expansion of hASCs
HASCs were derived from 23 liposuction aspirates.
Isolated hASCs generally presented a period of quiescen-
ce of about one week and then started to rapidly prolife-
rate, showing a homogeneous fibroblast-like shape (Fig.
de Girolamo et al
5
1a). We isolated an average of 3.5-4x105 progenitor cel-
ls/mL of raw adipose tissue and the proliferation rate of
hASCs was quite stable: in a month of culture we obtai-
ned between 108 and 109 cells from 5X105 hASCs; moreo-
ver, their proliferation rate and the cellular yield was unaf-
fected by cryopreservation (data not shown). The hASCs
growth rate was also maintained by growing cells in me-
dium supplemented with 5% FBS instead of 10%, whe-
reas cells cultured in 1% FBS were quiescent for more
than three weeks before showing apoptotic signals (data
not shown). The hASCs doubling time ranged between
60 and 90 hours, and under our experimental conditions
it depended on the cell plating density and on the time in
culture, but we did not observe any correlation with the
donor’s age. The clonogenic efficiency of hASCs remai-
ned constant until passage 4 (Fig.1b): indeed, at the first
passage, 13.2± 5.4% hASCs (n=4) were clonogenic and
this frequency was maintained to passage 4 (11.67±
2.52%). The hASC colony-forming capacity progressively
decreased starting from the fifth passage (7± 2%) until
the eighth passage, during which only 3± 2% of all cells
appeared to be clonogenic.
Phenotypic profile of hASCs: characterization by
FACS analysis
A representative cytofluorimetric analysis of hASCs at
passage IV is shown in Figures 1c to 1f. Cells appeared as
a homogenous population with a similar size and granula-
rity (Fig. 1c): 99% of hASCs expressed CD13 and 66% of
them co-expressed CD105 (Fig. 1d); 68% of hASCs are
CD44+ whereas almost 35% expressed CD49d while 28%
were CD44+-CD49d+ (Fig. 1e). As expected, hASCs were
CD45- (Fig. 1f). The phenotypic profiles of several hASCs
populations were quite similar, as shown in Table III.
Differentiation of Adipose-derived Stem Cells 
The multipotency of MSCs isolated from adult subcu-
taneous adipose tissue was examined by promoting dif-
ferentiation into chondrogenic, adipogenic and osteoge-
nic lineages (Fig. 2-7).
Chondrogenic and differentiation
HASCs were differentiated into chondrogenic lineage
under either monolayer or pellet conditions (micromass).
Although it is known that a three-dimensional environ-
Fig. 1 - Characterization of hASCs: cell-morphology, CFU-F and co-
expression of MSC markers: (a) Fibroblast-like morphology of hA-
SCs by phase contrast microscopy (40X magnification); (b) CFU-F
assay of hASC at passage I (dilution 12 cells/cm2); (c-f) FACS analy-
sis of hASC at passage IV stained with CD13, CD105, CD44, CD49d
and CD45 mAb. Size and granularity are depicted (c). The numbers
in the corners of each panel indicate the % of single- and double-
stained cells, gating the populations with specific isotype controls. 
TABLE III - hASCs PHENOTYPIC PROFILE
% positive cells
mean ± SD
CD 90 95.48 ± 5.35
CD 13 94.30 ± 8.36
CD 105 90.43 ± 11.83
CD 29 88.77 ± 20.40
CD 44 87.97 ± 11.43
CD 49d 78.90 ± 20.44
CD 54 77.86 ± 12.51
CD 34 5.51 ± 4.47
CD 14 2.96 ± 3.18
CD 45 2.16 ± 1.89
CD 71 1.52 ± 0.76
Flow cytometry analysis of cultured hASCs at passage IV, isolated from 5
independent donors. Results are expressed as % of positive cells (mean
± SD) gating the population with the isotype controls. Markers are listed
from the more to the less positive expression; markers under 5% of ex-
pression are to be considered negative.
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ment ameliorates chondrogenic differentiation, hASCs
cultured for three weeks in chondrogenic medium in the
wells were stained using Alcian blue (Fig. 2b), whereas
cells preserved in control medium were just barely stai-
ned (Fig. 2a). Primary chondrocytes were also included to
confirm the staining specificity (Fig. 2c). The staining de-
position was quantified by an image analysis tool: diffe-
rentiated hASCs contain 30% more glycosaminoglycans
than control cells (132.1 and 101.6 AU, respectively; data
not shown). Furthermore, to confirm chondrogenic diffe-
rentiation, type II collagen expression was analyzed by
immunofluorescence experiments. As shown in Figures
2e and 2f, only cells cultured for 21 days under chondro-
genic conditions and primary chondrocytes expressed ty-
pe II collagen, whereas no signal is present in undifferen-
tiated hASCs (Fig. 2d). Differentiated hASCs grown in pel-
let culture for 21 days generated bigger micromasses, as
shown in Figures 3a and 3b; the volume of differentiated
micromasses were significantly greater than the volumes
of the control ones (2.6mm3 compared to 0.6mm3;
p<.001, n=7), with an average increase of 305%. In addi-
tion, control micromasses appeared more fragile due to
the lack of extracellular matrix deposition (unpublished
observation). In the chondrogenic micromass, external
layer nuclei were abundant and cell morphology evoked
primary chondrocytes: cells showed an oval- and less fi-
broblast-like shape, nuclear membrane appeared quite ir-
regular, with some invaginations, and the cytoplasm was
more defined (Fig. 3c). Moreover, sections from the chon-
drogenic micromass were Alcian Blue positive (Fig 3d).
The sulfated GAG content was also quantified with the
DMMB assay: the chondrogenic differentiated samples
contained a significantly greater amount of GAGs
(3.53±0.2 µg/pellet; n=7, p<.001) with an average increa-
se of 130% compared to control samples (1.53±0.2
µg/pellet, n=7) (Fig. 4).
Adipogenic differentiation
hASCs differentiated towards adipocyte and produced
lipid vacuoles after only one week of differentiation; and
their size increased further when cells were cultured in
adipogenic conditions. Fourteen-day adipogenic-diffe-
rentiated hASCs were heavily stained by Oil Red O (Fig.
5b), in contrast to control hASCs, in which no stained va-
cuoles were detected (Fig. 5a). Quantitative analysis con-
firmed the observed increase of Oil Red staining in adipo-
genic-induced hASCs (data not shown).
Fig. 2 - Chondrogenic-differen-
tiated hASCs show glycosami-
noglycans  production and col-
lagen II expression compared to
undifferentiated hASCs: (a-c)
glycosaminoglycans staining by
Alcian Blue 8GX: monolayer
culture of hASCs maintained in
control (a) and chondrogenic
media (b) magnification). Pri-
mary chondrocytes (c) are
shown as positive control (100X
magnification); (d-h) collagen II
expression: immunofluorescen-
ce of control (d, g) and chon-
drogenic differentiated hASCs
(e, h) cultured for 21 days (630X
magnification) and of primary
chondrocytes (f) (400X magnifi-
cation). Cells are stained with a
mouse anti-human collagen II
revealed with a sheep α-muri-
ne-FITC Ab (d, e), and a rabbit
anti-human actin Ab revealed
with a goat α-rabbit-TRITC Ab
(g-h). 
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Osteogenic differentiation
HASCs were able to differentiate into osteoblast-like
cells, as demonstrated by cell-morphology change, cal-
cium deposition, osteopontin expression, and alkaline
phosphatase activity. Hematoxylin and eosin staining
highlighted morphological differences: undifferentiated
hASCs showed a fibroblast-like aspect (Fig. 6a), whe-
reas osteogenic-differentiated hASCs were less out-
stretched, with a cubical shape (Fig. 6b). Furthermore, 
hASCS differentiated for 28 days (Fig. 6d) produced
abundant mineralized calcium-positive nodules on the
cell surface, in contrast to control cells, in which the
calcified matrix was almost undetectable (Fig. 6c). The
calcified matrix of the osteogenic-differentiated hASCs
increased more than three times compared to the con-
trol ones (data not shown). To monitor the early hASC
osteogenic differentiation process, we looked for the
expression of early osteogenic markers such as osteo-
pont in (OPN) and alkal ine phosphatase (ALP).  
Intracellular OPN expression was induced in 14-day
differentiated hASCs (Fig. 6f), whereas it was undetec-
table in undifferentiated cells (Fig. 6e). Osteosarcoma
SaOs-2 cells were OPN-positive (Fig. 6g). The study of
alkaline phosphatase activity (ALP) at different time
points (7, 14 and 21 days) in four different hASCs po-
pulations cultured in CTRL and osteogenic medium
showed that differentiated hASCs produced a signifi-
cant level of ALP after 14 days of differentiation
(between 13% and 37% compared to control cells)
(Fig. 7a-d). Moreover, two samples slightly increased
their ALP activity (Figs. 7a-b) after only 7 days of diffe-
rentiation, and a significant, although variable, upregu-
Fig. 3 - Micromasses of chondrogenic differentiated hASCs show an
increase in extracellular matrix production compared to undifferen-
tiated ones: (a-c) microphotographs of sections of hASCs micro-
masses cultured for 21 days in control (a) and chondrogenic (b) me-
dia and stained with Haematoxilin/Eosin (100X magnification); (c)
magnification of the section of the chondrogenic pellet (400X magni-
fication); (d) section of a chondrogenic differentiated micromass
stained by Alcian Blue 8GX (400X magnification). 
Fig. 4 - Micromasses of chondrogenic differentiated hASCs show an
increase in sulfated GAGs production.
Glycosaminoglycans  quantification by DMMB assay of control
(CTRL) and chondrogenic differentiated (CDR) micromasses expres-
sed as µg GAG content for each pellet. Data are depicted as box-
plot: the box represents first quartile, median and third quartile; the
whiskers represent the 10-90% of the interval; the dots represent the
outliers. Unpaired Student’s t-test was performed (**= p< .01).
Fig. 5 - Adipogenic-differentiated hASCs show lipid vacuole forma-
tion. hASCs cultured for 14 days in control (a) and adipogenic (b)
media (200X magnification): lipid vacuoles are positively stained by
Oil Red O and counterstained with hematoxylin.
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lation was maintained until 21 days in three out of the
four samples (Figs. 7a-c). However, in one sample alone,
ALP increased after 14 days of differentiation and signifi-
cantly decreased at day 21 (Fig. 7d). We suggest that the
kinetic enzymatic differences observed in our samples
may be due to the basal ALP activity of the CTRL cells.
Differentiated hASCs interact with natural and
synthetic scaffolds 
The ability of hASCs to adhere to scaffolds routinely
applied in orthopedics and oral implantology was tested
by seeding them on biomaterials such as hydroxyapati-
te granules (HAP), human cancellous bone fragments,
titanium, and deproteinized bovine bone (Bio-Oss®).
HASCs cultured for at least two weeks adhered quite
well to all the tested scaffolds and they proliferated in
the same way as cells maintained in culture wells (poly-
styrene) (Figs. 8b-f). Moreover, hASCs properly coloni-
zed and overwhelmed the surface and pores of all the
biomaterials, as shown on HAP (Fig. 8a); no cellular
toxicity due to the release of any substances from
scaffolds was observed. 
Undifferentiated hASCs seeded on HAP, human bone
and deproteinized bovine bone fragments were able to
produce a greater amount of calcium compared to hA-
SCs grown on polystyrene (Figs. 9a-b, empty bars), indi-
cating that they have their own osteoinductive properties
Fig. 7 - Osteogenic-differentiated hASC show an increase in alkaline phosphatase activity compared to undifferentiated ones. Kinetic study of
alkaline phosphatase activity (ALP) of hASCs from four donors (a-d) in control (empty bars) and osteogenic (grey bars) cultured for 7, 14 and 21
days. Each bar represents the mean±SD (n=3 independent experiments for each cell population) of normalized values of ALP units for µg of
protein.Two-way ANOVA analysis was also performed: **= p<.01 OM vs CTRL.
Fig. 6 - Osteogenic-differentiated
hASCs show a different morpho-
logy and expression of specific
osteogenic markers compared to
undifferentiated hASCs: (a-b)
morphology of 14-day cultured
hASCs in control (a) and osteoge-
nic (b) media (200X magnifica-
tion); (c-d) Alizarin Red S staining
of extracellular calcified matrix of
control (c) and osteogenic-diffe-
rentiated hASCs (d) cultured for
21 days. Osteopontin expression
(e-j): immunofluorescence of con-
trol (e, h) and osteogenic differen-
tiated hASCs (f, i) cultured for 14
days. SaOs-2 cells (g, j) are
shown as positive control. Cells
are stained with a rabbit  anti-hu-
man osteopontin Ab revealed with
a goat α-rabbit-TRITC Ab (e-g)
and a mouse anti-human α-tubu-
lin mAb revealed with a sheep 
α-murine-FITC Ab (h-j) (400x 
magnification).
de Girolamo et al
9
even in the absence of any specific differentiative bioche-
mical stimuli. In particular, undifferentiated hASCs grown
on HAP and human bone for 14 days (Fig. 9a) produced
an average increase of 36% and 174%, respectively,
compared to undifferentiated cells grown for the same
amount of time on polystyrene. The same phenomenon is
detectable after five weeks in undifferentiated cells cultu-
red on deproteinized bovine bone (Bio-Oss®): indeed, this
scaffold enhanced their calcium deposition by 173%
compared to undifferentiated hASCs grown on polystyre-
ne for the same period of time (Fig. 9b). 
Cells cultured on monolayer for two weeks in osteoge-
nic medium showed a calcium deposition increase of
29% with respect to undifferentiated hASCs (Fig. 9a); this
up-regulation was strongly enhanced for hASCs cultured
in osteogenic medium and seeded on scaffold. Indeed,
for differentiated cells grown on titanium, we measured
an increase of 106% compared to control cells grown on
polystyrene, an increase of 138% for differentiated hA-
SCs cultured on HAP, and an increase of 468% for those
on human bone fragments (Fig 9a). After 5 weeks of cul-
ture, the amount of calcium deposition in differentiated
hASCs cultured on monolayer further increased by 95%
compared to hASCs cultured in control medium. The
amount of calcium produced by differentiated hASCs
seeded on HAP was further enhanced: it was 216% grea-
ter than control hASCs cultured on polystyrene, and an
even more significant increase of 546% was observed in
cells seeded on deproteinized bovine bone (Fig. 9b). 
DISCUSSION 
In the last few years, tissue engineering and regenerati-
ve medicine are becoming prominent fields in research
and in modern medicine due to the aging population and
to the shortage of donor tissues (24, 25). A convenient
cellular source for autologous cells will aid the approach
of regenerative medicine and we think that mesenchymal
stem cells derived from adipose tissue present several
advantages compared to BMSC. Indeed, fat is routinely
available in large amounts from liposuction and a copious
number of MSCs can be isolated from a minimal amount
of withdrawn tissue (26, 27), with minimal discomfort for
the patient compared to bone marrow aspiration. Moreo-
ver, the number of purified progenitor cells is quite abun-
dant (12). Here we report that, independently of the age
of the donor, hASCs proliferate quite constantly over an
extended period of time while showing clonogenic acti-
vity and a stable phenotypic profile, thus confirming data
Fig. 8 - Osteogenic differentiated hASCs seeded on scaffolds display good adhesive properties. HASCs maintained in control and osteogenic
media for 14 days on monolayer were seeded for 14 additional days on scaffolds. (a-b) Osteogenic differentiated hASCs on HAP granules: op-
tical microphotograph (a) 40X magnification) and (b) SEM picture; (c-d) SEM pictures of control (c) and osteogenic differentiated hASCs (d)
seeded on human cancellous bone fragments; (e-f) SEM pictures of osteogenic differentiated hASC seeded on on a titanium screw (e) and on
a Bio-Oss® fragment (f). 
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from other laboratories (12, 24, 28, 29). Interestingly
enough, and in contrast with the defined mesenchymal
stromal cells markers expression (30, 31), in some popu-
lations we found a consistent number of hASCs expres-
sing CD34, as also described by others (11, 32). Further
studies on the characterization of the CD34+ population
are in progress to evaluate if sorted hASC-subpopula-
tions (32, 33) are directed towards a prominent osteo-
specificity in vitro, likely permitting more rapid and effi-
cient future applications.
HASCs differentiated in vitro towards chondrocytes
and adipocyte-like cells (15, 26, 28, 34). Our data showed
that the enhancement of GAG deposition is really due to
the chondrogenic differentiation process. Although we
showed a significant increase of volume of the chondro-
genic micromasses compared to undifferentiated ones,
the data on DNA content (not shown) suggested that the
increase in volume is only partially due to cell prolifera-
tion, and thus it is correlated to a greater GAG-positive
matrix production in differentiated samples. 
The chondrogenic differentiation of hASCs is not yet
well documented in an in vivo study, whereas several re-
ports on plastic surgery validate the presence of progeni-
tor cells in fat that do not only fill the damaged adipose
tissue, but also reduce fibrotic scar formation due to re-
vascularization (35, 36). The broad potential clinical appli-
cation of hASCs is also be based on their ability to diffe-
rentiate towards endothelial (25,37) (unpublished data)
and muscle cells (13), making them a promising tool for
regeneration of highly vascularized bones and in the car-
diovascular field, respectively.
In this study we focused our interest on the osteogenic
potential of hASCs, showing that, at the early stage of the
differentiation process, ALP activity and osteopontin ex-
pression were significantly upregulated, as was the calci-
fied matrix production when the time of differentiation
was extended. The observed different ALP activity modu-
lation did not always correlate with the later abundant
calcified matrix formation, and we might explain this re-
sult by the fact that we did not specifically analyze only
the newly synthesized enzyme (GPI-linked ALP fraction),
but rather, the whole ALP enzymatic pool. Indeed, we
performed preliminary experiments on soluble and GPI-
linked ALP fractions isolated from control and osteoge-
nic-induced hASCs; we observed that the GPI-linked
compartment derived from differentiated hASCs contai-
ned more than double the ALP activity of the same frac-
tion derived from control hASCs, indicating that the enzy-
me is rapidly upregulated during differentiation (unpubli-
shed data). The cellular localization of osteopontin, usual-
ly abundant in bone tissue, where it regulates mineraliza-
tion by acting on bone cell adhesion and the osteoclast
function, appears during the differentiation process: we
detected OPN expression predominantly in the Golgi and
in Endoplasmic Reticulum Compartment, confirming its
peculiar secretory pathway (38). However, we also obser-
ved an OPN nuclear localization, as described by Junaid
et al (39), which could be correlated either with cell divi-
sion or with an early differentiation state of some hASCs
(data not shown).
Fig. 9 - Scaffolds support and promote osteogenic differentiation of hASCs. Extracellular calcified matrix quantification of hASCs cultured in
monolayer and in the presence of scaffolds after 2 weeks (a) and 5 weeks (b). Each bar is represented as mean ± SD (n=3). One-way ANOVA
was also performed: **= p<.01 OM vs CTRL; ## = p<.01 CTRL cells on scaffold vs CTRL cells alone; §§ = p<.01 OM cells on scaffold vs OM cells
alone.
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HASCs were induced to differentiate into osteoblast-like
cells both by biochemical stimuli and by the physical inte-
raction with scaffolds. Interestingly enough, the adherence
of hASCs to the tested scaffolds induced hASCs to sponta-
neously differentiate. We are uncertain whether this is due
to the chemical features of the scaffolds or more to the 3D
structure, which may allow the hASCs to activate specific
intracellular pathways that cause extracellular matrix depo-
sition. To address this issue, other types of scaffold need to
be analyzed. Moreover, the same number of hASCs loaded
on scaffolds and induced to differentiate in osteogenic me-
dium for 15 days were able to produce a more abundant
calcified extracellular matrix deposition compared to cells
cultured on polystyrene, showing a synergistic effect of the
osteogenic medium whose magnitude appeared to depend
on the characteristics of the biomaterial, such as chemical
properties, porosity, roughness and others. In particular, hy-
droxyapatite, human bone and deproteinized bovine bone
fragments seemed more osteoinductive compared to tita-
nium, despite the fact that hASCs seeded on titanium
screws produced levels of calcified matrix significantly
greater than those produced by hASCs plated on polystyre-
ne. Human bone fragments appeared to be the most rapid
osteogenic inducers for the hASCs, suggesting the use of
constructs made with hASCs and bone fragment for the
treatment of large bone defects.
We have also shown that the calcium production is time
dependent; indeed, the calcified matrix produced by hA-
SCs differentiated on HAP granules significantly increased
after five weeks compared to the one formed in two weeks.
We observed that hASCs directly differentiated in the pre-
sence of the scaffolds,  and produced a level of calcified
extracellular matrix that was similar to the one produced by
cells pre-differentiated on polystyrene and loaded on the
scaffold next (unpublished observation). Thus, loading un-
differentiated hASCs directly on scaffolds could shorten the
time between the adipose tissue removal and the use of dif-
ferentiated cells, allowing faster clinical application.
In the near future, due to the large number of hASCs and
their rapid osteogenic differentiation in vitro, it will be feasi-
ble to test several types of scaffolds, and to use them to
study the effect of additional osteogenic stimulants, like Bo-
ne Morphogenetic Proteins (BMPs) and other growth fac-
tors, and their combined action. However, we are still at the
beginning and many other aspects need to be addressed
further, such as the behavior of hASCs seeded on scaffolds
and cultured in bioreactors under dynamic conditions, and
their osteogenic differentiation capacity in critical osteoarti-
cular defects in animal models (37, 40). 
In conclusion, human ASCs may be considered an easily
accessible cellular source, and consequently a possible fu-
ture tool for autologous cell-based regeneration of skeletal
defects in orthopedics and oral implantology. Moreover, hA-
SCs may be a convenient cellular model for studying biolo-
gical differentiation processes and an ideal system for
screening drugs which could affect osteogenic progenitor
cells and thus skeletal-tissue repair and bone metabolism. 
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